AlphAIalphai — Financial news for AI agents
themarketsdaily.comJUN 25 min read$PMI

PMI (NYSEAMERICAN:PMI) Short Interest Down 57.2% in May

PMI’s short interest fell 57.2% in May, dropping to 475,224 shares as of May 15 from 1,110,773 on April 30, with a short-interest ratio of 0.1 days and about 0.5% of shares sold short. Analysts: HC Wainwright started coverage with a neutral rating; Zacks upgraded to hold. PMI reported May 15 quarterly EPS of -$0.10 on revenue of $1.15M.

Original reporting
themarketsdaily.com
Published Jun 2, 2026, 3:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 4:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
PMI (NYSEAMERICAN:PMI) Short Interest Down 57.2% in May — source image
Source · themarketsdaily.com
Decision brief

The 30-second read

$PMINeutralLow
01

Why it matters

For PMI, the actionable element is the 57.2% short-interest reduction; macro PMI commentary is more relevant to broad cyclical sentiment than to a total artificial heart manufacturer.

02

Market read

Lower short interest may reduce downside pressure, but the article does not introduce a new company catalyst beyond the already-reported May 15 earnings.

03

What to watch

The stock’s extremely low price/liquidity profile (sub-$0.20 print mentioned) means flows and spread dynamics can dominate any short-interest signal.

Relevance 6/10Novelty 4/10Timing: Post–May short-interest update (as of May 15) with stock trading up on the day of publication

Background

The piece combines a short-interest update for PMI with a roundup of US/global PMI macro prints and a brief recap of PMI’s recent earnings.

Company-level read

Ticker impact

$PMINeutralMedium confidence
Context

The article is directly about PMI’s short-interest decline (down 57.2% in May) and includes its latest earnings snapshot and trading move.

Expected impact

Near-term: modest support possible from lower borrow/cover dynamics; direction likely remains sentiment/microcap-driven without new company-specific news.

Evidence & confidence

The only company-specific datapoint is the short-interest change; earnings were reported May 15 and no new guidance/contract/litigation is introduced.

Market effects

Sector

Macro ISM manufacturing strength may marginally improve risk appetite for economically sensitive names, but PMI is a medical-tech company and the link is indirect.

Regional

US manufacturing data strength is US-centric; mixed international PMIs suggest uneven global demand backdrop.

Global

Global PMI mix (China/services vs factory moderation; Europe softer) implies stabilization rather than broad acceleration.

Counterpoint

What could challenge this read

Short interest can drop for reasons unrelated to fundamentals (e.g., covering ahead of liquidity events), so it may not translate into sustained upside.

Key entities

  • public_company
    PMI

    Picard Medical Inc; article cites May 15 short interest (475,224 shares) and April 30 comparison (1,110,773 shares).

Read at source← All news

Related articles

JUL 27
$PMIMedAI 8/10

PMI revenues top $11bn as IQOS grows share in Global Travel Retail

Philip Morris International reported Q2 2026 net revenues of $11.2bn, up 10.4% year on year and 7.6% organically. Gross profit rose to $7.7bn and operating income to $4.5bn. Smoke-free shipments increased 7.5%, with IQOS holding a 21.5% Global Travel Retail airport offtake share (Mar-May). PMI plans $1.4bn-$1.6bn capex for 2026.

dfnionline.com6 min
JUN 3
$BJDXMedAI 9/10

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

Healthcare stocks rose Tuesday on multiple biotech updates. Bluejay Diagnostics (BJDX) surged 100% after a strategic partnership with Argonaut to advance its Symphony diagnostic platform and announced a private placement up to $23.6M. Picard Medical (PMI) gained 60.33% after completing animal implant studies of its Emperor total artificial heart. Legend Biotech (LEGN) rose 42.22% ahead of EHA Phase 1 data. CUE climbed 18.93% with board changes. Cingulate (CING) rose 11.94% despite the FDA declin

finanzen.ch6 min
JUN 3
$BJDXMedAI 9/10

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

Healthcare biotech gainers on Tuesday included Bluejay Diagnostics (BJDX), which said it signed a strategic partnership with Argonaut to support its Symphony near-patient diagnostic platform; BJDX shares rose 100% to $4.34 and the company also announced a private placement up to $23.6M. Picard Medical (PMI) reported completed animal implant studies for its next-gen Emperor total artificial heart; shares rose 60.33% to $0.27. Legend Biotech (LEGN) said it will present Phase 1 data for LB2501 show

rttnews.com5 min
JUN 2
$PMIMedAI 8/10

Picard Medical / SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies

Picard Medical (NYSE American: PMI), parent of SynCardia, said it completed an acute in vivo implant study series of its next-generation Emperor Total Artificial Heart at the University of Arizona and Banner University Medical Center. Three procedures showed stable full circulatory support with no device-related intraoperative failures, using an independent dual-motor ventricular design. The Emperor TAH remains under development and is not FDA approved.

manilatimes.net4 min
AUG 8
$BTGMedAI 8/10

B2Gold Shares Surge 23% After Mali Permit Boosts Fekola Growth Outlook

B2Gold’s shares (BTG) rose 23.1% to $5.03 on Aug. 7 after Mali issued the Menankoto permit for the Fekola mine. B2Gold said Fekola Regional targets over 150,000 ounces annually from 2028 and tightened 2026 production guidance to 820,000–920,000 ounces. Adjusted EPS was $0.03 vs $0.07 consensus; cash was $287m.

ts2.tech6 min